Patient Satisfaction and Convenience Increased with Current Hereditary Angioedema Treatment Options, According to Study

    Patient Satisfaction and Convenience Increased with Current Hereditary
          Angioedema Treatment Options, According to Study Findings

Analysis also reveals decrease in emergency room visits and hospitalizations

PR Newswire

SAN DIEGO, March 1, 2014

SAN DIEGO, March 1, 2014 /PRNewswire/ --Findings announced by CSL
Behringtoday show that current hereditary angioedema (HAE) treatment options,
such as C1 Esterase Inhibitor (C1-INH) concentrate, are allowing for greater
patient satisfaction, higher rates of home treatment and a decrease in the
number of hospitalizations and visits to the emergency room. HAE is a rare,
potentially fatal swelling disorder caused by a deficiency of C1-INH. Until
recently, only limited therapeutic options were available for patients in the
U.S. with the condition. Today, HAE patients can choose from multiple options
to address their condition. The 46-question online survey of physicians, which
was conducted between March and June 2013, closely patterned after an initial
survey conducted between October 2009 and February 2010. The data were
presented at the 2014 American Academy of Allergy, Asthma & Immunology (AAAAI)
Annual Meeting.

"The previously conducted survey revealed wide variability in HAE management,
leaving questions about the impact of newer treatment options and changes in
HAE care," said Marc A. Riedl, MD, MS, Associate Professor of Medicine and
Section Head of Clinical Immunology and Allergy at the UCLA David Geffen
School of Medicine, and one of the study's investigators. "As our results have
shown, current treatment practices now align more closely with current HAE
treatment guidelines, with patients demonstrating an increase in satisfaction
and physicians noticing improved patient outcomes."

Current HAE guidelines from the World Allergy Organization recommend that all
acute attacks be considered for on-demand treatment, and that such treatment
be mandatory for attacks affecting upper airways. The guidelines further state
that on-demand treatment be given as early in the attack as possible.
According to study findings, there was a three-fold increase in the percentage
of attacks self-treated at home (8 percent to 27 percent; P<0.00005).
Additionally, the study found convenience was reported more frequently as an
important treatment decision driver for patients (27 percent versus 10
percent; P<0.00005). Based on these treatment strategies, the percentage of
patients perceived by physicians to be very satisfied with HAE treatment
increased from 13 percent to 40 percent (P<0.00005).

Additional findings note that preferences toward danazol, an often-used
steroid treatment, have decreased from 56 percent to 23 percent (P<0.00005).
Decreases were also observed in HAE attack-related emergency room visits (62
percent to 54 percent; P=NS) and hospitalizations (13 percent to 3 percent;

About Hereditary Angioedema
HAE is a rare genetic disorder caused by a deficiency of C1 Esterase
Inhibitor. It is inherited in an autosomal dominant manner. Symptoms of HAE
include episodes of edema – or swelling – in the face, abdomen, larynx and
extremities. Patients who have abdominal attacks of HAE can experience
episodes of extreme pain, diarrhea, nausea and vomiting caused by swelling of
the intestinal wall. HAE attacks that involve the face or throat can result in
airway closure, asphyxiation and, if untreated, death. Diagnosis of HAE
requires a blood test to confirm low or abnormal levels of C1 Esterase

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed
to saving lives and improving the quality of life for people with rare and
serious diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders
including hemophilia and von Willebrand disease, primary immune deficiencies,
hereditary angioedema and inherited respiratory disease, and neurological
disorders in certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent hemolytic
diseases in the newborn. CSL Behring is a subsidiary of CSL Limited, a
biopharmaceutical company with headquarters in Melbourne, Australia. For more
information, visit CSL Behring operates one of the world's
largest plasma collection networks, CSL Plasma.

Sheila A. Burke
Director, Communications & Public Relations
Worldwide Commercial Operations
CSL Behring
O: 610-878-4209


Press spacebar to pause and continue. Press esc to stop.